1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020;91:157–160.

2. Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. N Engl J Med 2020;383:1757–1766.

4. Lee H, Choi H, Yang B, et al. Interstitial lung disease increases susceptibility to and severity of COVID-19. Eur Respir J 2021;58:2004125.

5. Li HH, Liu CC, Hsu TW, et al. Upregulation of ACE2 and TMPRSS2 by particulate matter and idiopathic pulmonary fibrosis: a potential role in severe COVID-19. Part Fibre Toxicol 2021;18:11.

6. Kondoh Y, Kataoka K, Ando M, et al. COVID-19 and acute exacerbation of interstitial lung disease. Respir Investig 2021;59:675–678.

7. Lee YH, Kim CH, Lee J. Coronavirus disease 2019 pneumonia may present as an acute exacerbation of idiopathic pulmonary fibrosis. J Thorac Dis 2020;12:3902–3904.

8. Cilli A, Hanta I, Uzer F, et al. Characteristics and outcomes of COVID-19 patients with IPF: a multi-center retrospective study. Respir Med Res 2022;81:100900.

9. Drake TM, Docherty AB, Harrison EM, et al.; ISARIC4C Investigators. Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study. Am J Respir Crit Care Med 2020;202:1656–1665.

10. Esposito AJ, Menon AA, Ghosh AJ, et al. Increased odds of death for patients with interstitial lung disease and COVID-19: a case-control study. Am J Respir Crit Care Med 2020;202:1710–1713.

11. Gallay L, Uzunhan Y, Borie R, et al. Risk factors for mortality after COVID-19 in patients with preexisting interstitial lung disease. Am J Respir Crit Care Med 2021;203:245–249.

12. Ouyang L, Gong J, Yu M. Pre-existing interstitial lung disease in patients with coronavirus disease 2019: a meta-analysis. Int Immunopharmacol 2021;100:108145.

13. Shin DW, Cho J, Park JH, Cho B. National general health screening program in Korea: history, current status, and future direction: a scoping review. Precis Future Med 2022;6:9–31.

14. Choi H, Han K, Jung JH, et al. Long-term mortality of tuberculosis survivors in Korea: a population-based longitudinal study. Clin Infect Dis 2023;76:e973–e981.

15. Kim BG, Lee H, Yeom SW, et al. Increased risk of new-onset asthma after COVID-19: a nationwide population-based cohort study. J Allergy Clin Immunol Pract 2024;12:120–132.e5.

16. Kim BG, Lee H, Jeong CY, et al. Risk of newly diagnosed interstitial lung disease after COVID-19 and impact of vaccination: a nationwide population-based cohort study. Front Public Health 2024;11:1295457.

17. Haam JH, Kim BT, Kim EM, et al. Diagnosis of obesity: 2022 update of clinical practice guidelines for obesity by the Korean Society for the Study of Obesity. J Obes Metab Syndr 2023;32:121–129.

18. Kim BG, Lee H, Kang MG, Kim JS, Moon JY. Risk of ischemic heart disease in chronic obstructive pulmonary disease: a nationwide cohort study. J Korean Med Sci 2023;38:e344.

19. Kim SH, Han K, Park J, et al. Association between non-cystic fibrosis bronchiectasis and the risk of incident dementia: a nationwide cohort study. Chron Respir Dis 2023;20:14799731231222282.

20. Kim T, Choi H, Lee H, et al. Impact of allergic disease on the risk of mycobacterial disease. J Allergy Clin Immunol Pract 2023;11:2830–2838.e4.

21. Lee H, Ryu J, Chung SJ, et al. Overall and respiratory mortality reduction with physical activity in subjects with and without asthma. Allergy 2023;78:1677–1680.

22. Choi H, Han K, Jung JH, et al. Impact of rheumatoid arthritis and seropositivity on the risk of non-cystic fibrosis bronchiectasis. Chest 2024;165:1330–1340.

23. Yang B, Kim BG, Han K, et al. Systemic sclerosis and risk of bronchiectasis: a nationwide longitudinal cohort study. Arthritis Res Ther 2023;25:209.

24. Lee HR, Yoo JE, Choi H, et al. Tuberculosis and the risk of ischemic heart disease: a nationwide cohort study. Clin Infect Dis 2023;76:1576–1584.

25. Yoo JE, Choi H, Han K, et al. Tuberculosis and risk of Parkinson’s disease: a nationwide cohort study. Pulmonology 2023;29:250–252.

26. Yeo Y, Yoo JE, Han K, et al. Risk of dementia in survivors of active tuberculosis in Korea: a nationwide cohort study. J Infect Public Health 2024;17:286–292.

27. Kim Y, Yoon JH, Ryu J, et al. Gastroesophageal reflux disease increases susceptibility to nontuberculous mycobacterial pulmonary disease. Chest 2023;163:270–280.

28. Kim KH. Comorbidity adjustment in health insurance claim database. Health Policy Manag 2016;26:71–78.

29. Moon SM, Choi H, Kim SH, et al. Increased lung cancer risk and associated risk factors in tuberculosis survivors: a Korean population-based study. Clin Infect Dis 2023;77:1329–1339.

30. Zhang Z, Kim HJ, Lonjon G, Zhu Y, written on behalf of AME Big-Data Clinical Trial Collaborative Group. Balance diagnostics after propensity score matching. Ann Transl Med 2019;7:16.

31. Bocchino M, Rea G, Capitelli L, Lieto R, Bruzzese D. Chest CT lung abnormalities 1 year after COVID-19: a systematic review and meta-analysis. Radiology 2023;308:e230535.

32. Fabbri L, Moss S, Khan FA, et al. Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis. Thorax 2023;78:191–201.